A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants with Advanced Solid Tumors Previously Treated with Standard of Care Therapy

Trial Identifier: D702EC00001
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: November 2025
Primary Completion Date: July 2027
Study Completion Date: July 2029
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
ES Barcelona, ES, 08035
ES Barcelona, ES, 08036
ES Madrid, ES, 28040
ES Madrid, ES, 28027
GB Newcastle upon Tyne, GB, NE7 7DN
GB Sutton, GB, SM2 5PT
KR Seoul, KR, 03080
US, NC Huntersville, NC, US, 28078
US, TX San Antonio, TX, US, 78229
US, VA Fairfax, VA, US, 22031